Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

scientific article

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1126/SCIENCE.1101637
P3181OpenCitations bibliographic resource ID1012694
P698PubMed publication ID15284455
P5875ResearchGate publication ID8426409

P50authorDaniel HaberQ5217393
P2093author name stringDaphne W Bell
Jeffrey Settleman
Raffaella Sordella
P433issue5687
P407language of work or nameEnglishQ1860
P921main subjectlung cancerQ47912
apoptotic processQ14599311
P304page(s)1163-7
P577publication date2004-08-20
P1433published inScienceQ192864
P1476titleGefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways
P478volume305

Reverse relations

cites work (P2860)
Q36883649"Who should receive epidermal growth factor receptor inhibitors for non-small cell lung cancer and when?".
Q36254754(Z)3,4,5,4'-trans-tetramethoxystilbene, a new analogue of resveratrol, inhibits gefitinb-resistant non-small cell lung cancer via selectively elevating intracellular calcium level.
Q299989982004: Signaling Breakthroughs of the Year
Q339378763,3'-Diindolylmethane (DIM) inhibits the growth and invasion of drug-resistant human cancer cells expressing EGFR mutants
Q36028935A Novel Technique to Detect EGFR Mutations in Lung Cancer.
Q33994726A Pilot Study of Preoperative Gefitinib for Early-Stage Lung Cancer to Assess Intratumor Drug Concentration and Pathways Mediating Primary Resistance
Q61444296A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer
Q36488342A critical appraisal of prognostic and predictive factors for common lung cancers.
Q34492884A multiscale computational approach to dissect early events in the Erb family receptor mediated activation, differential signaling, and relevance to oncogenic transformations
Q92517460A novel bis-aryl urea compound inhibits tumor proliferation via cathepsin D-associated apoptosis
Q36376408A review of erlotinib and its clinical use.
Q42498384A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and ligand-dependent EGFR activity
Q92783310ADAM17: An Emerging Therapeutic Target for Lung Cancer
Q36313197AKT crystal structure and AKT-specific inhibitors
Q41201253AKT-STAT3 Pathway as a Downstream Target of EGFR Signaling to Regulate PD-L1 Expression on NSCLC cells.
Q39623714AXL regulates mesothelioma proliferation and invasiveness
Q30931456Aberrant trafficking of NSCLC-associated EGFR mutants through the endocytic recycling pathway promotes interaction with Src.
Q33947959Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy.
Q54561321Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.
Q34626608Acetylation of EGF receptor contributes to tumor cell resistance to histone deacetylase inhibitors
Q24816331Acquired gefitinib-resistant mutation of EGFR in a chemonaive lung adenocarcinoma harboring gefitinib-sensitive mutation L858R
Q24794765Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
Q36910173Acquired substrate preference for GAB1 protein bestows transforming activity to ERBB2 kinase lung cancer mutants
Q35971676Activating Akt and the brain's resources to drive cellular survival and prevent inflammatory injury
Q38494311Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma.
Q40176065Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation
Q41471047Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC)
Q36128435Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Q33636907Activation of the signal transducer and activator of transcription 3 pathway up-regulates estrogen receptor-beta expression in lung adenocarcinoma cells
Q34516556Adeno-associated virus vector mediated expression of an oncogenic retroviral envelope protein induces lung adenocarcinomas in immunocompetent mice
Q41546742Akt Signaling Is Sustained by a CD44 Splice Isoform-Mediated Positive Feedback Loop
Q39263992Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations
Q24301372Akt phosphorylates and suppresses the transactivation of retinoic acid receptor alpha
Q41478504Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer
Q36973814Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy
Q36669872Alterations in EGFR and related genes following neo-adjuvant chemotherapy in Chinese patients with non-small cell lung cancer
Q37273963Alternate paths from epidermal growth factor receptor to Akt in malignant versus nontransformed lung epithelial cells: ErbB3 versus Gab1.
Q35578544Amiloride sensitizes human pancreatic cancer cells to erlotinib in vitro through inhibition of the PI3K/AKT signaling pathway
Q54124211Amino acid starvation culture condition sensitizes EGFR-expressing cancer cell lines to gefitinib-mediated cytotoxicity by inducing atypical necroptosis.
Q33731181Amphiregulin promotes BAX inhibition and resistance to gefitinib in non-small-cell lung cancers.
Q24541450Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752
Q88377651An EGFR ligand promotes EGFR-mutant but not KRAS-mutant lung cancer in vivo
Q53222808An EGFR/PI3K/AKT axis promotes accumulation of the Rac1-GEF Tiam1 that is critical in EGFR-driven tumorigenesis.
Q39009616An activation of LC3A-mediated autophagy contributes to de novo and acquired resistance to EGFR tyrosine kinase inhibitors in lung adenocarcinoma
Q24293598An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor
Q36493654An electrostatic engine model for autoinhibition and activation of the epidermal growth factor receptor (EGFR/ErbB) family
Q34407919An in vivo C. elegans model system for screening EGFR-inhibiting anti-cancer drugs
Q40200097An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer
Q35058437Analysis of Somatic Mutations in Cancer: Molecular Mechanisms of Activation in the ErbB Family of Receptor Tyrosine Kinases
Q57763142Analysis of potential receptor tyrosine kinase targets in intimal and mural sarcomas
Q41612476Anti-tumor efficacy of theliatinib in esophageal cancer patient-derived xenografts models with epidermal growth factor receptor (EGFR) overexpression and gene amplification
Q36466443Anticipating clinical resistance to target-directed agents : the BCR-ABL paradigm
Q35480110Apoptosis-inducing effects of cetuximab combined with radiotherapy and hypothermia on human nasopharyngeal carcinoma CNE cells
Q27016160Apoptotic agents
Q36430311Applications of genomics in NSCLC.
Q58712613Arsenic circumvents the gefitinib resistance by binding to P62 and mediating autophagic degradation of EGFR in non-small cell lung cancer
Q43061603Assessing the roles of EGFR gene copy number, protein expression and mutation in predicting outcomes in non-small-cell lung cancer after treatment with EGFR inhibitors
Q37052272Assessment of epidermal growth factor receptor status in glioblastomas
Q28550377Association Study of a Functional Variant on ABCG2 Gene with Sunitinib-Induced Severe Adverse Drug Reaction
Q37141943Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells
Q26866067At the crossroads: EGFR and PTHrP signaling in cancer-mediated diseases of bone
Q36445905BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia.
Q50288616Binding of CBL to ligand-responsive p-6Y-EGFR mutants
Q50288609Binding of GRB2:GAB1 complex to ligand-responsive p-6Y-EGFR mutants
Q50288599Binding of GRB2:SOS1 complex to phosphorylated ligand-responsive EGFR mutants
Q50288610Binding of PI3K to complex of GRB2:GAB1 and ligand-responsive p-6Y-EGFR mutants
Q50288601Binding of SHC1 to p-6Y-EGFR mutants
Q36540571Biological and clinical implications of EGFR mutations in lung cancer.
Q37988924Biomarkers and transcriptome profiling of lung cancer
Q36040606Biomarkers that currently affect clinical practice: EGFR, ALK, MET, KRAS
Q34331327Blocking airway mucous cell metaplasia by inhibiting EGFR antiapoptosis and IL-13 transdifferentiation signals.
Q92134610Brain metastases in oncogene-driven non-small cell lung cancer
Q38840383Breaking the crosstalk of the cellular tumorigenic network: Hypothesis for addressing resistances to targeted therapies in advanced NSCLC.
Q35196999Butein, a novel dual inhibitor of MET and EGFR, overcomes gefitinib-resistant lung cancer growth
Q90370821CNOT3 targets negative cell cycle regulators in non-small cell lung cancer development
Q37051421CUSTOM-SEQ: a prototype for oncology rapid learning in a comprehensive EHR environment
Q58802947Calpain 2 knockdown promotes cell apoptosis and restores gefitinib sensitivity through epidermal growth factor receptor/protein kinase B/survivin signaling
Q94348851Cancer Cell: Linking Oncogenic Signaling to Molecular Structure
Q47386350Cancer stem cell-like population is preferentially suppressed by EGFR-TKIs in EGFR-mutated PC-9 tumor models
Q36092823Carcinogenesis, cancer therapy and chemoprevention
Q39205831Caspase-independent cell death is involved in the negative effect of EGF receptor inhibitors on cisplatin in non-small cell lung cancer cells.
Q48283327Chalcone-templated Hsp90 inhibitors and their effects on gefitinib resistance in non-small cell lung cancer (NSCLC).
Q34778365Characteristics of CD8+ T cell subsets in Chinese patients with chronic HIV infection during initial ART.
Q48687589Characterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib
Q91955116Characterization of epidermal growth factor receptor (EGFR) P848L, an unusual EGFR variant present in lung cancer patients, in a murine Ba/F3 model
Q38731759Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line.
Q55369035Characterizing Cancer Drug Response and Biological Correlates: A Geometric Network Approach.
Q37004639Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives
Q33523195Chemosensitization of cancer cells by siRNA using targeted nanogel delivery
Q52640291Cigarette smoke enhances oncogene addiction to c-MET and desensitizes EGFR-expressing non-small cell lung cancer to EGFR TKIs.
Q42109363Circulating exosomal microRNA-96 promotes cell proliferation, migration and drug resistance by targeting LMO7.
Q28077340Circulating tumor cells versus circulating tumor DNA in lung cancer-which one will win?
Q29615475Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
Q46815372Clinical and molecular predictors of response to EGFR tyrosine kinase inhibitors in non-small cell lung cancer
Q36111249Clinical applications for targeted therapy in bladder cancer
Q46446185Clinical benefit in NSCLC: advanced-stage patients require symptom-improving palliation. Experiences from the 'Iressa' expanded access program
Q44634377Clinical development of targeted moledular cancer drugs
Q37220488Clinical features reflect exon sites of EGFR mutations in patients with resected non-small-cell lung cancer
Q37334996Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis
Q38041563Clinical testing for molecular targets for personalized treatment in lung cancer.
Q80100938Clinico-pathological and biological significance of tyrosine kinase domain gene mutations and overexpression of epidermal growth factor receptor for lung adenocarcinoma
Q33571227Clinicopathological features of Chinese lung cancer patients with epidermal growth factor receptor mutation
Q33614314Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC.
Q41811594Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET.
Q33332189Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas
Q37080964Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients
Q54977986Combined caveolin-1 and epidermal growth factor receptor expression as a prognostic marker for breast cancer.
Q50056486Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis.
Q38335360Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors
Q34560075Comparing antibody and small-molecule therapies for cancer
Q36882732Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC.
Q36865316Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS
Q39378163Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples.
Q37657511Concomitant high gene copy number and protein overexpression of IGF1R and EGFR negatively affect disease-free survival of surgically resected non-small-cell-lung cancer patients
Q42066649Conditional deletion of Pten causes bronchiolar hyperplasia
Q28386290Constitutive activation of epidermal growth factor receptor promotes tumorigenesis of Cr(VI)-transformed cells through decreased reactive oxygen species and apoptosis resistance development
Q24302510Contribution of the orphan nuclear receptor Nur77 to the apoptotic action of IGFBP-3
Q52983736Contribution of ¹⁸Fluorodeoxyglucose positron emission tomography uptake and TTF-1 expression in the evaluation of the EGFR mutation in patients with lung adenocarcinoma.
Q37109227Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia.
Q41606248Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
Q50288611Conversion of PIP2 to PIP3 by PI3K bound to ligand-responsive p-6Y-EGFR mutants
Q37393014Cooperative interaction between protein inhibitor of activated signal transducer and activator of transcription-3 with epidermal growth factor receptor blockade in lung cancer.
Q36287463Correlation between serum CEA levels and EGFR mutations in Chinese nonsmokers with lung adenocarcinoma
Q46171346Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma.
Q92969824Coxsackievirus Type B3 Is a Potent Oncolytic Virus against KRAS-Mutant Lung Adenocarcinoma
Q46194088Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas
Q33710152Critical appraisal of the role of gefitinib in the management of locally advanced or metastatic non-small cell lung cancer
Q37287006Cross-arm binding efficiency of an EGFR x c-Met bispecific antibody.
Q36429474Crossing the rubicon in lung adenocarcinoma: the conundrum of EGFR tyrosine kinase mutations
Q36849663Current practices and guidelines for clinical next-generation sequencing oncology testing
Q34637939Cyclooxygenase-2 transactivates the epidermal growth factor receptor through specific E-prostanoid receptors and tumor necrosis factor-alpha converting enzyme
Q34283737Dasatinib worsens the effect of cetuximab in combination with fractionated radiotherapy in FaDu- and A431-derived xenografted tumours
Q36284940Deciphering the Key Features of Malignant Tumor Microenvironment for Anti-cancer Therapy
Q40135901Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling.
Q37690668Deguelin Potentiates Apoptotic Activity of an EGFR Tyrosine Kinase Inhibitor (AG1478) in PIK3CA-Mutated Head and Neck Squamous Cell Carcinoma.
Q38853191Delivery strategies and potential targets for siRNA in major cancer types
Q34970672Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells
Q54431224Deregulation of STAT-5 isoforms in the development of HPV-mediated cervical carcinogenesis.
Q39437297Detection of epidermal growth factor receptor mutations in a few cancer cells from transbronchial cytologic specimens by reverse transcriptase-polymerase chain reaction
Q39531710Detection of low-level EGFR T790M mutation in lung cancer tissues
Q40251398Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors
Q39129178Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution (Review).
Q90229878Development and Evaluation of Multifunctional Poly(Lactic-co-glycolic acid) Nanoparticles Embedded in Carboxymethyl β-Glucan Porous Microcapsules as a Novel Drug Delivery System for Gefitinib
Q37630493Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer
Q34000934Development of transcriptomic biomarker signature in human saliva to detect lung cancer
Q33747930Diacylglycerol kinase delta and protein kinase C(alpha) modulate epidermal growth factor receptor abundance and degradation through ubiquitin-specific protease 8.
Q38930336Diagnosis and Molecular Classification of Lung Cancer
Q35434274Differential Effects of Tyrosine Kinase Inhibitors on Normal and Oncogenic EGFR Signaling and Downstream Effectors
Q42131816Diminished functional role and altered localization of SHP2 in non-small cell lung cancer cells with EGFR-activating mutations
Q39781895Discovery and Biological Evaluation of Novel Dual EGFR/c-Met Inhibitors
Q35540678Discovery and anti-cancer evaluation of two novel non-ATP-competitive FGFR1 inhibitors in non-small-cell lung cancer
Q38889564Discovery of 2',4'-dimethoxychalcone as a Hsp90 inhibitor and its effect on iressa-resistant non-small cell lung cancer (NSCLC).
Q58860040Discovery of dually acting small-molecule inhibitors of cancer-resistance relevant receptor tyrosine kinases EGFR and IGF-1R
Q34701319Discovery of selective and noncovalent diaminopyrimidine-based inhibitors of epidermal growth factor receptor containing the T790M resistance mutation
Q36547770Dissecting cancer pathways and vulnerabilities with RNAi
Q51769749Dissecting cell signaling pathways with genetically encoded 3-iodo-L-tyrosine.
Q50288615Dissociation of phosphorylated PLCG1 from ligand-responsive p-6Y-EGFR mutants
Q42484909Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants
Q58200558Divergent Synthesis of Quinazolines Using Organocatalytic Domino Strategies under Aerobic Conditions
Q51214174Diversity of epidermal growth factor receptor-mediated activation of downstream molecules in human lung carcinomas.
Q43191223Downregulation of miR-21 enhances chemotherapeutic effect of taxol in breast carcinoma cells
Q28471948Drosophila cbl is essential for control of cell death and cell differentiation during eye development
Q36040613Drug resistance and its significance for treatment decisions in non-small-cell lung cancer
Q28254233Drugging the cancer kinome: progress and challenges in developing personalized molecular cancer therapeutics
Q63989113Dual Inhibitors-Loaded Nanotherapeutics that Target Kinase Signaling Pathways Synergize with Immune Checkpoint Inhibitor
Q28385103E-cadherin negatively regulates neoplastic growth in non-small cell lung cancer: role of Rho GTPases
Q29619032EGF-ERBB signalling: towards the systems level
Q40235641EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer
Q42513590EGFR Mutations Compromise Hypoxia-Associated Radiation Resistance through Impaired Replication Fork-Associated DNA Damage Repair
Q42701535EGFR T790M: revealing the secrets of a gatekeeper
Q36048238EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort
Q51340775EGFR exon 19 in-frame deletion and polymorphisms of DNA repair genes in never-smoking female lung adenocarcinoma patients.
Q27851583EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer
Q36306259EGFR inhibitors: what have we learned from the treatment of lung cancer?
Q36758325EGFR kinase domain mutations - functional impact and relevance for lung cancer therapy
Q46717312EGFR mRNA is upregulated, but somatic mutations of the gene are hardly found in renal cell carcinoma in Japanese patients.
Q35164306EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry
Q36844366EGFR mutation status in plasma and tumor tissues in non-small cell lung cancer serves as a predictor of response to EGFR-TKI treatment
Q26852507EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer
Q54538162EGFR mutations in non-small-cell lung cancer among smokers and non-smokers: a meta-analysis.
Q35800614EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib.
Q46677125EGFR somatic doublets in lung cancer are frequent and generally arise from a pair of driver mutations uncommonly seen as singlet mutations: one-third of doublets occur at five pairs of amino acids
Q39362508EGFR tyrosine kinase mutation testing in the treatment of non-small-cell lung cancer
Q39538057EGFR upregulates inflammatory and proliferative responses in human lung adenocarcinoma cell line (A549), induced by lower dose of cadmium chloride
Q36026188EGFR-L858R mutant enhances lung adenocarcinoma cell invasive ability and promotes malignant pleural effusion formation through activation of the CXCL12-CXCR4 pathway
Q39106976EGFR-activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity
Q51040009EGFR-mediated apoptosis via STAT3.
Q34356008EGFs and ERBBs—Brief history and prospects
Q27851440EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer
Q38805633EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer
Q29619520ERBB receptors and cancer: the complexity of targeted inhibitors
Q38919117ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas
Q37153622ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer
Q52649612ERK inhibition represses gefitinib resistance in non-small cell lung cancer cells.
Q37661108ERK1/2 blockade prevents epithelial-mesenchymal transition in lung cancer cells and promotes their sensitivity to EGFR inhibition
Q33727478Effect of Paris saponin I on radiosensitivity in a gefitinib-resistant lung adenocarcinoma cell line
Q42660638Effect of weekly or daily dosing regimen of Gefitinib in mouse models of lung cancer
Q55012925Effects of general anesthesia with or without epidural block on tumor metastasis and mechanisms.
Q39515313Effects of respiratory mechanical forces on the pharmacological response of lung cancer cells to chemotherapeutic agents
Q37691441Emerging MEK inhibitors.
Q42869980Endocytosis and cancer
Q34606927Enhanced T cell lymphoma in NOD.Stat5b transgenic mice is caused by hyperactivation of Stat5b in CD8+ thymocytes
Q38798148Enhanced gefitinib-induced repression of the epidermal growth factor receptor pathway by ataxia telangiectasia-mutated kinase inhibition in non-small-cell lung cancer cells
Q54531321EphB3 suppresses non-small-cell lung cancer metastasis via a PP2A/RACK1/Akt signalling complex.
Q88776744Epidermal growth factor receptor (EGFR) T790M mutation identified in plasma indicates failure sites and predicts clinical prognosis in non-small cell lung cancer progression during first-generation tyrosine kinase inhibitor therapy: a prospective ob
Q36458742Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy
Q39828582Epidermal growth factor receptor (EGFR) mutation and p-EGFR expression in resected non-small cell lung cancer
Q54361563Epidermal growth factor receptor (EGFR) mutations as biomarker for head and neck squamous cell carcinomas (HNSCC).
Q42818168Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations
Q35793804Epidermal growth factor receptor as a novel molecular target for aggressive papillary tumors in the middle ear and temporal bone
Q46371923Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy
Q44485092Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer
Q34557318Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer
Q44051250Epidermal growth factor receptor gene mutations in papillary thyroid carcinoma
Q37634598Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer
Q35013457Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy
Q36504349Epidermal growth factor receptor inhibition and non-small cell lung cancer
Q64234550Epidermal growth factor receptor inhibition attenuates non-alcoholic fatty liver disease in diet-induced obese mice
Q36429442Epidermal growth factor receptor inhibitors in cancer treatment.
Q36830108Epidermal growth factor receptor inhibitors in non-small cell lung cancer
Q37252270Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas
Q29615474Epidermal growth factor receptor mutations in lung cancer
Q36817294Epidermal growth factor receptor mutations in lung cancers.
Q39918647Epidermal growth factor receptor mutations in non-small cell lung cancer influence downstream Akt, MAPK and Stat3 signaling
Q39752055Epidermal growth factor receptor signaling in nonsmall cell lung cancer
Q34561698Epidermal growth factor receptor signaling synergizes with Hedgehog/GLI in oncogenic transformation via activation of the MEK/ERK/JUN pathway
Q36850793Epidermal growth factor receptor tyrosine phosphorylation and signaling controlled by a nuclear receptor coactivator, amplified in breast cancer 1.
Q36493232Epidermal growth factor receptor-targeted agents for lung cancer
Q33779882Epidermal growth factor receptors with tyrosine kinase domain mutations exhibit reduced Cbl association, poor ubiquitylation, and down-regulation but are efficiently internalized
Q36674536Epidermal growth factor regulates hematopoietic regeneration after radiation injury
Q28084034Epidermal growth factor signaling in transformed cells
Q36042698Epidermal growth factor signals regulate dihydropyrimidine dehydrogenase expression in EGFR-mutated non-small-cell lung cancer.
Q38714404Epigallocatechin-3-gallate augments the therapeutic effects of benzo[a]pyrene-mediated lung carcinogenesis
Q38150749Epistatic interactions and drug response
Q24535592Epithelial membrane protein-1 is a biomarker of gefitinib resistance.
Q37977436Epithelial mesenchymal transition and lung cancer
Q38729111ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology
Q33928631ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines
Q37249978ErbBs in lung cancer
Q40251565Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
Q58615775Essential roles of mitochondrial and heme function in lung cancer bioenergetics and tumorigenesis
Q37728841Establishment and characterization of primary lung cancer cell lines from Chinese population
Q37399540Ethnic differences and functional analysis of MET mutations in lung cancer
Q40018113Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors.
Q37589516Evolving Cancer Classification in the Era of Personalized Medicine: A Primer for Radiologists
Q29615120Exploiting the PI3K/AKT pathway for cancer drug discovery
Q37818230Exploration of synthetic lethal interactions as cancer drug targets
Q54388141Expression of EGFR and molecules downstream to PI3K/Akt, Raf-1-MEK-1-MAP (Erk1/2), and JAK (STAT3) pathways in invasive lung adenocarcinomas resected at a single institution.
Q49887971Expression, regulation and targeting of receptor tyrosine kinases in esophageal squamous cell carcinoma.
Q33684453Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer
Q28252845Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
Q26830811From modules to medicine: How modular domains and their associated networks can enable personalized medicine
Q36457037From the bench to the bed: individualizing treatment in non-small-cell lung cancer
Q36120023Functional analysis of cancer-associated EGFR mutants using a cellular assay with YFP-tagged EGFR intracellular domain
Q54977360Functional cooperation between HIF-1α and c-Jun in mediating primary and acquired resistance to gefitinib in NSCLC cells with activating mutation of EGFR.
Q37040827Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer
Q40161268Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib
Q80100963Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study
Q28485309Gefitinib analogue V1801 induces apoptosis of T790M EGFR-harboring lung cancer cells by up-regulation of the BH-3 only protein Noxa
Q37290533Gefitinib and high-dose fractionated radiotherapy for carcinomatous encephalitis from non-small cell lung carcinoma.
Q40418546Gefitinib in combination with oxaliplatin and 5-fluorouracil in irinotecan-refractory patients with colorectal cancer: a phase I study of the Arbeits gemeinschaft Internistische Onkologie (AIO).
Q36161284Gefitinib in non-small cell lung cancer
Q36610166Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Q34447234Gefitinib loaded folate decorated bovine serum albumin conjugated carboxymethyl-beta-cyclodextrin nanoparticles enhance drug delivery and attenuate autophagy in folate receptor-positive cancer cells
Q39054011Gefitinib resistance resulted from STAT3-mediated Akt activation in lung cancer cells
Q30544631Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study
Q45169148Gefitinib--a novel targeted approach to treating cancer
Q28469345Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics
Q35580846Gefitinib-mediated reactive oxygen specie (ROS) instigates mitochondrial dysfunction and drug resistance in lung cancer cells
Q33207883Gefitinib: a review of its use in the management of advanced non-small-cell lung cancer
Q30988680Gene set analysis exploiting the topology of a pathway.
Q36393012Genetic alterations in urothelial bladder carcinoma: an updated review
Q37113682Genetic predictors of MEK dependence in non-small cell lung cancer
Q33313648Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers
Q36195093Genomic and Transcriptomic Alterations Associated with STAT3 Activation in Head and Neck Cancer
Q27851633Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors
Q37699199Gli1 promotes colorectal cancer metastasis in a Foxm1-dependent manner by activating EMT and PI3K-AKT signaling
Q80051640Global profiling of EGFR gene mutation, amplification, regulation and tissue protein expression in unknown primary carcinomas: to target or not to target?
Q37828397Glutaminase: a hot spot for regulation of cancer cell metabolism?
Q90429716Gossypol Inhibits Non-small Cell Lung Cancer Cells Proliferation by Targeting EGFRL858R/T790M
Q34908845Growth factor receptors and apoptosis regulators: signaling pathways, prognosis, chemosensitivity and treatment outcomes of breast cancer.
Q33699007HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation
Q36615002HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients
Q38615197HER3/ErbB3, an emerging cancer therapeutic target
Q36249234Have we made progress in pharmacogenomics? The implementation of molecular markers in colon cancer
Q33336861High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies
Q51753083Higher expression of chemokine receptor CXCR7 is linked to early and metastatic recurrence in pathological stage I nonsmall cell lung cancer.
Q37068513Highly parallel identification of essential genes in cancer cells
Q38858961Honokiol targets mitochondria to halt cancer progression and metastasis
Q37588365How and when to use genetic markers for nonsmall cell lung cancer.
Q36429550How will lung cancer be treated in the future?
Q37772399Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls.
Q39960713Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance
Q40352167Hsp90 inhibitors cause G2/M arrest associated with the reduction of Cdc25C and Cdc2 in lung cancer cell lines
Q64058267Hypoxia-inducible factor-1α and nuclear factor-κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells
Q30877356Identification and preliminary characterization of novel small molecules that inhibit growth of human lung adenocarcinoma cells
Q28548412Identification of Biomarker and Co-Regulatory Motifs in Lung Adenocarcinoma Based on Differential Interactions
Q39707468Identification of biomarkers in human head and neck tumor cell lines that predict for in vitro sensitivity to gefitinib
Q28477481Identification of potent EGFR inhibitors from TCM Database@Taiwan
Q46557776Identification of the rare EGFR mutation p.G796S as somatic and germline mutation in white patients with squamous cell carcinoma of the head and neck
Q36127636Identifying EGFR mutation-induced drug resistance based on alpha shape model analysis of the dynamics
Q58582701Identifying EGFR-Expressed Cells and Detecting EGFR Multi-Mutations at Single-Cell Level by Microfluidic Chip
Q35264584Identifying erlotinib-sensitive non-small cell lung carcinoma tumors in mice using [(11)C]erlotinib PET.
Q38420747Identifying novel targets of oncogenic EGF receptor signaling in lung cancer through global phosphoproteomics.
Q36423688Immunogenetic programs for viral induction of mucous cell metaplasia
Q51046274Immunohistochemistry with a novel mutation-specific monoclonal antibody as a screening tool for the EGFR L858R mutational status in primary lung adenocarcinoma.
Q39712642Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations
Q39701114In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines.
Q54379896In vivo activation of the PI3K-Akt pathway in mouse beta cells by the EGFR mutation L858R protects against diabetes.
Q60921926Incense burning smoke sensitizes lung cancer cells to EGFR TKI by inducing AREG expression
Q33686369Increased MIR31HG lncRNA expression increases gefitinib resistance in non-small cell lung cancer cell lines through the EGFR/PI3K/AKT signaling pathway
Q36082004Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphisms
Q36026392Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas
Q46782213Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.
Q37602377Inhibiting PI3K as a therapeutic strategy against cancer
Q35928707Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growth
Q36795358Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer
Q33227206Inhibition of EGFR signaling: all mutations are not created equal
Q33571026Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel
Q38866417Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells
Q37460333Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy
Q34581860Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo
Q92134225Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S
Q24301761Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface
Q53794752Inhibitor Response to HER2 G776(YVMA) In-frame Insertion in HER2-positive Breast Cancer.
Q33401214Input-output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data
Q27725743Insight into the Inhibition of Drug-Resistant Mutants of the Receptor Tyrosine Kinase EGFR
Q40440883Insulin-activated, K+-channel-sensitive Akt pathway is primary mediator of ML-1 cell proliferation
Q55055524Interferon (alpha, beta and omega) receptor 2 is a prognostic biomarker for lung cancer.
Q38364439Intracellular signals of lung cancer cells as possible therapeutic targets
Q35994416Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition
Q33700689Intratumoral distribution of EGFR mutations and copy number in metastatic lung cancer, what impact on the initial molecular diagnosis?
Q24603941Intratumoral epiregulin is a marker of advanced disease in non-small cell lung cancer patients and confers invasive properties on EGFR-mutant cells
Q35474544Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin β1/FAK signaling
Q37512570Investigational agents in the management of non-small cell lung cancer.
Q38323440Investigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeutics.
Q33821320Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
Q39328532JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation
Q53608822Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia.
Q80202684KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance
Q53242395KL-6 and CEA levels in epithelial lining fluid microsamples predict response to gefitinib in patients with advanced non-small cell lung cancer.
Q21563446KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
Q46555496Killing time for cancer cells
Q54978633Knockdown of annexin A5 restores gefitinib sensitivity by promoting G2/M cell cycle arrest.
Q46965909Lack of prognostic value of EGFR mutations in primary resected non-small cell lung cancer
Q36640684Laricitrin suppresses increased benzo(a)pyrene-induced lung tumor-associated monocyte-derived dendritic cell cancer progression
Q33358603Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type
Q48231295Lessons to be Learned: The Molecular Basis of Kinase-Targeted Therapies and Drug Resistance in Non-Small Cell Lung Cancer.
Q35566222Ligand-independent phosphorylation of Y869 (Y845) links mutant EGFR signaling to stat-mediated gene expression
Q37488529Liver kinase B1 expression promotes phosphatase activity and abrogation of receptor tyrosine kinase phosphorylation in human cancer cells
Q39642171Loss of PTEN Expression by Blocking Nuclear Translocation of EGR1 in Gefitinib-Resistant Lung Cancer Cells Harboring Epidermal Growth Factor Receptor–Activating Mutations
Q37438296Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers
Q34666826Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors
Q64086539Lung cancer stem cells and their aggressive progeny, controlled by EGFR/MIG6 inverse expression, dictate a novel NSCLC treatment approach
Q34541960Lung cancer therapeutics that target signaling pathways: an update
Q39741320Lung cancers unrelated to smoking: characterized by single oncogene addiction?
Q24309725Lyn, a Src family kinase, regulates activation of epidermal growth factor receptors in lung adenocarcinoma cells
Q36265149MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibition
Q54166640Management Strategies for Adverse Events Associated With EGFR TKIs in Non-Small Cell Lung Cancer.
Q90300758Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer
Q27679902Mechanism for activation of mutated epidermal growth factor receptors in lung cancer
Q42043613Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients
Q50146512Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors.
Q36559283Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy
Q41918077Mechanisms of human cytomegalovirus infection with a focus on epidermal growth factor receptor interactions
Q37766260Mechanistic insights into acquired drug resistance in epidermal growth factor receptor mutation-targeted lung cancer therapy
Q38683133Medullary Thyroid Cancer: Clinical Characteristics and New Insights into Therapeutic Strategies Targeting Tyrosine Kinases
Q35844565Mesenchymal Stem Cell Therapy Alleviates Interstitial Cystitis by Activating Wnt Signaling Pathway
Q37274389MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers
Q33527586MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol
Q64875418MicroRNA-7 facilitates the degradation of alpha-synuclein and its aggregates by promoting autophagy
Q39890068Mitogen-activated protein kinase phosphatase-1 modulated JNK activation is critical for apoptosis induced by inhibitor of epidermal growth factor receptor-tyrosine kinase
Q28484612Modeling of tumor progression in NSCLC and intrinsic resistance to TKI in loss of PTEN expression
Q26771116Molecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics-Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-Cancer
Q36612550Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis.
Q24606677Molecular biology of lung cancer
Q24610335Molecular biology of lung cancer: clinical implications
Q33969308Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study
Q34778891Molecular characteristics of non-small cell lung cancer with reduced CHFR expression in The Cancer Genome Atlas (TCGA) project
Q42822469Molecular dynamics analysis of conserved hydrophobic and hydrophilic bond-interaction networks in ErbB family kinases
Q48451660Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography.
Q37061902Molecular imaging of nonsmall cell lung carcinomas expressing active mutant EGFR kinase using PET with [(124)i]-morpholino-IPQA
Q38060727Molecular mechanisms of lung-specific toxicity induced by epidermal growth factor receptor tyrosine kinase inhibitors
Q37602884Molecular modeling of ErbB4/HER4 kinase in the context of the HER4 signaling network helps rationalize the effects of clinically identified HER4 somatic mutations on the cell phenotype
Q27691299Molecular pathology of lung cancer: key to personalized medicine
Q36772562Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer
Q36498832Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer
Q33609045Molecular systems biology of ErbB1 signaling: bridging the gap through multiscale modeling and high-performance computing
Q36547758Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors
Q26824599Molecular testing in lung cancer in the era of precision medicine
Q35854276Monitoring of cyclooxygenase-2 levels can predict EGFR mutations and the efficacy of EGFR-TKI in patients with lung adenocarcinoma
Q39455567Moving towards molecular-guided treatments: erlotinib and clinical outcomes in non-small-cell lung cancer patients
Q36936796Multimodality imaging of the HER-kinase axis in cancer
Q39246320Multiple analyses of G-protein coupled receptor (GPCR) expression in the development of gefitinib-resistance in transforming non-small-cell lung cancer
Q33915992Multiple roles and therapeutic implications of Akt signaling in cancer.
Q35106771Multiscale computational models in physical systems biology of intracellular trafficking
Q38816286Mutant Proteogenomics
Q52642806Mutation abundance affects the therapeutic efficacy of EGFR-TKI in patients with advanced lung adenocarcinoma: A retrospective analysis.
Q40149065Mutation and polymorphism in the EGFR-TK domain associated with lung cancer.
Q40237141Mutation profile of EGFR gene detected by denaturing high-performance liquid chromatography in Japanese lung cancer patients
Q36824808Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduction and tumorigenesis
Q54671910Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas.
Q24669579Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas
Q35551048Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking
Q35380919N-cadherin expression is a potential survival mechanism of gefitinib-resistant lung cancer cells
Q36508097New and emerging radiosensitizers and radioprotectors
Q42024692New targets and challenges in the molecular therapeutics of cancer
Q34657670Nexus of signaling and endocytosis in oncogenesis driven by non-small cell lung cancer-associated epidermal growth factor receptor mutants.
Q54948216Non-invasive tumor genotyping using radiogenomic biomarkers, a systematic review and oncology-wide pathway analysis.
Q47146342Non-small cell lung cancer (NSCLC), EGFR downstream pathway activation and TKI targeted therapies sensitivity: Effect of the plasma membrane-associated NEU3.
Q28278682Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship
Q37692660Non-small-cell lung cancer harbouring mutations in the EGFR kinase domain
Q35063410Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells
Q90349512Oligosaccharyltransferase Inhibition Overcomes Therapeutic Resistance to EGFR Tyrosine Kinase Inhibitors
Q33569458Oligosaccharyltransferase inhibition induces senescence in RTK-driven tumor cells
Q35623817Oncogenes come of age.
Q36762385Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment
Q33902463Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation
Q34323807Oncogenic potential is related to activating effect of cancer single and double somatic mutations in receptor tyrosine kinases
Q24810573Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants
Q38520010Opportunities and challenges in using studies without a control group in comparative effectiveness reviews
Q37697442Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site
Q24678516Overexpression of PIAS3 suppresses cell growth and restores the drug sensitivity of human lung cancer cells in association with PI3-K/Akt inactivation
Q35763328Overview of the development of personalized genomic medicine and surgery
Q58091925Oxytetracycline have the therapeutic efficiency in CD133 HCC population through suppression CD133 expression by decreasing of protein stability of CD133
Q55012187PHLDA2 is a key oncogene-induced negative feedback inhibitor of EGFR/ErbB2 signaling via interference with AKT signaling.
Q55256271PI3K/AKT inhibition induces compensatory activation of the MET/STAT3 pathway in non-small cell lung cancer.
Q33870342PIK3CA mutations and copy number gains in human lung cancers
Q39826662PKC-delta binds to E-cadherin and mediates EGF-induced cell scattering
Q92669056PKCα is required for Akt-mTORC1 activation in non-small cell lung carcinoma (NSCLC) with EGFR mutation
Q50288612PLCG1 binds to ligand-responsive p-6Y-EGFR mutants
Q36187706PML represses lung cancer metastasis by suppressing the nuclear EGFR-mediated transcriptional activation of MMP2.
Q44846498PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients.
Q35653997PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with gefitinib therapy
Q42944759PUMA Kills Stem Cells to Stall Cancer?
Q34300057PUMA induction by FoxO3a mediates the anticancer activities of the broad-range kinase inhibitor UCN-01.
Q33857728PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells
Q38831311Panaxydol, a component of Panax ginseng, induces apoptosis in cancer cells through EGFR activation and ER stress and inhibits tumor growth in mouse models
Q37398845Parameters for individualizing systemic therapy in non-small cell lung cancer
Q35584647Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects
Q28657698Pathway analysis for drug repositioning based on public database mining
Q34781357Pathways driving the endocytosis of mutant and wild-type EGFR in cancer
Q61451510Pathways regulating the expression of the immunomodulatory protein glycodelin in non‑small cell lung cancer
Q36117926Performance comparison of two commercial human whole-exome capture systems on formalin-fixed paraffin-embedded lung adenocarcinoma samples.
Q28586781Personalized characterization of diseases using sample-specific networks
Q36817080Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer
Q57177486Personalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspective
Q37412844Perspectives in mammalian IGFBP-3 biology: local vs. systemic action
Q24339394Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms
Q36313181Perturbations of the AKT signaling pathway in human cancer
Q34042708Pgrmc1 (progesterone receptor membrane component 1) associates with epidermal growth factor receptor and regulates erlotinib sensitivity
Q28278381Pharmacodynamic biomarkers for molecular cancer therapeutics
Q38262008Pharmacogenomic biomarkers for personalized cancer treatment.
Q36966043Pharmacogenomics of lung cancer: with a view to address EGFR-targeted therapies
Q56446183Pharmacogenomics steps toward personalized medicine
Q38803038Pharmacokinetic variations in cancer patients with liver dysfunction: applications and challenges of pharmacometabolomics
Q36219744Phosphoproteomics for oncology discovery and treatment
Q27851872Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
Q36632245Point mutations of protein kinases and individualised cancer therapy
Q40213093Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB.
Q39049572Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non-Small-Cell Lung Cancer
Q26863474Preclinical Murine Models for Lung Cancer: Clinical Trial Applications
Q36547786Predicting clinical benefit in non-small-cell lung cancer patients treated with epidermal growth factor tyrosine kinase inhibitors
Q38390126Predicting resistance by selection of signaling pathways
Q40053178Prediction of EGFR and KRAS mutation in non-small cell lung cancer using quantitative 18F FDG-PET/CT metrics
Q45116933Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839).
Q57896476Predictive Tumor Biomarkers for EGFR Inhibitors
Q35076206Predictive and prognostic markers for epidermal growth factor receptor inhibitor therapy in non-small cell lung cancer
Q39640248Predictive biomarkers in the management of EGFR mutant lung cancer
Q35875753Present and Future of EGFR Inhibitors for Head and Neck Squamous Cell Cancer
Q37799825Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer
Q27852993Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients
Q37996270Prognostic and predictive value of cell cycle deregulation in non-small-cell lung cancer
Q54632156Prognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapy.
Q64235237Prognostic impact of pleural effusion in EGFR-mutant non-small cell lung cancer patients without brain metastasis
Q90087574Prognostic value of EGFR 19-del and 21-L858R mutations in patients with non-small cell lung cancer
Q38187627Prognostic value of phospho-Akt in patients with non-small cell lung carcinoma: a meta-analysis
Q35632548Progression-free Survival Decreases with Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials
Q36235591Promises and pitfalls in the prediction of antiepidermal growth factor receptor activity
Q36337922Prospects of RNA interference therapy for cancer
Q38759724Protein Kinase G facilitates EGFR-mediated cell death in MDA-MB-468 cells
Q35203134Protein domain-level landscape of cancer-type-specific somatic mutations
Q39976000Protein kinase C-theta regulates KIT expression and proliferation in gastrointestinal stromal tumors
Q36463998Protein kinases and phosphatases as therapeutic targets in cancer.
Q36969009Proteins, drug targets and the mechanisms they control: the simple truth about complex networks
Q42096010Pyridones as Highly Selective, Noncovalent Inhibitors of T790M Double Mutants of EGFR.
Q28540324QSAR-based models for designing quinazoline/imidazothiazoles/pyrazolopyrimidines based inhibitors against wild and mutant EGFR
Q37330722Quantitative modeling perspectives on the ErbB system of cell regulatory processes
Q37302721Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors
Q37340472Quantitative prediction of fold resistance for inhibitors of EGFR.
Q37649220Quantitative proteomic profiling identifies protein correlates to EGFR kinase inhibition
Q35051834RAC1 inhibition as a therapeutic target for gefitinib-resistant non-small-cell lung cancer
Q34138262RADical response puts an exceptional responder in CHKmate: a synthetic lethal curative response to DNA-damaging chemotherapy?
Q57293866RASPELD to Perform High-End Screening in an Academic Environment toward the Development of Cancer Therapeutics
Q35934254RNAi and HTS: exploring cancer by systematic loss-of-function
Q42700759RPN2 promotes colorectal cancer cell proliferation through modulating the glycosylation status of EGFR
Q33873095Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer
Q33948614Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M.
Q35789960Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas
Q42204869Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine
Q46486238Rationale for combination use of targeted agents in ovarian cancer: do we have one?
Q36318531Recent advances in targeted therapy of human myelogenous leukaemia
Q36491838Recent advances in targeting regulators of apoptosis in cancer cells for therapeutic gain
Q21092930Recent advances of novel targeted therapy in non-small cell lung cancer
Q38023942Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer.
Q43095950Reconstruction of an integrated genome-scale co-expression network reveals key modules involved in lung adenocarcinoma
Q33838524Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis.
Q54561641Reliability of the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations integrated into the clinical practice for non-small cell lung cancers.
Q35166782Renal cell carcinoma and the use of sorafenib
Q24658420Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses
Q38256553Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma
Q55178886Response to HER2 Inhibition in a Patient With Brain Metastasis With EGFR TKI Acquired Resistance and an HER2 Amplification.
Q46941491Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor
Q33576476Response to erlotinib in recurrent glioblastoma multiforme showing coexpression of EGFRvIII and PTEN.
Q36225230Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha
Q44843905Restriction endonuclease-mediated real-time digestion-PCR for somatic mutation detection
Q37093554Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population
Q35584486Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer
Q54340378Role of [¹⁸F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer.
Q37331465Role of apoptosis in colon cancer biology, therapy, and prevention
Q34417886Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer
Q53687949Role of long non-coding RNA in drug resistance in non-small cell lung cancer.
Q33576845Role of network branching in eliciting differential short-term signaling responses in the hypersensitive epidermal growth factor receptor mutants implicated in lung cancer
Q50288600SOS-mediated nucleotide exchange of RAS (mediated by GRB2:SOS1 in complex with ligand-responsive p-6Y-EGFR mutants)
Q50288606SOS-mediated nucleotide exchange of RAS (mediated by GRB2:SOS1 in complex with phosphorylated SHC1 and ligand-responsive p-6Y-EGFR mutants)
Q53058056Schedule-dependent synergistic interaction between docetaxel and gefitinib in NSCLC cell lines regardless of the mutation status of EGFR and KRAS and its molecular mechanisms.
Q38829545Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib
Q58151801Selective Energy Transfer Between Quantum Dots and Gold Nanoparticles for Detection of Multiple Mutations in Epidermal Growth Factor Receptor
Q36616873Selective inhibition of TNF-alpha-induced activation of mitogen-activated protein kinases and metastatic activities by gefitinib
Q45058705Selective targeting of point-mutated KRAS through artificial microRNAs
Q41483948Sensitive genotyping of mutations in the EGFR gene from NSCLC patients using PCR-GoldMag lateral flow device.
Q37468539Sensitivity and resistance to EGF-R inhibitors: approaches to enhance the efficacy of EGF-R antibodies
Q34274373Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks.
Q37378176Sequential molecular changes during multistage pathogenesis of small peripheral adenocarcinomas of the lung
Q46946875Serum carcinoembryonic antigen level is associated with epidermal growth factor receptor mutations in recurrent lung adenocarcinomas
Q44715034Sex difference in the influence of smoking status on the responsiveness to gefitinib monotherapy in adenocarcinoma of the lung: Okayama Lung Cancer Study Group experience
Q35176147Short-hairpin RNA library: identification of therapeutic partners for gefitinib-resistant non-small cell lung cancer
Q35987785Signaling multiplex of the epidermal growth factor receptor
Q36392991Signaling networks assembled by oncogenic EGFR and c-Met
Q54964048Significant Effect of Anti-tyrosine Kinase Inhibitor (Gefitinib) on Overall Survival of the Glioblastoma Multiforme Patients in the Backdrop of Mutational Status of Epidermal Growth Factor Receptor and PTEN Genes.
Q36395322Simulation of the Protein-Shedding Kinetics of a Fully Vascularized Tumor.
Q40230093Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5-fluorouracil and docetaxel in head and neck squamous cell carcinoma
Q37638679Small-molecule inhibitors of the human epidermal receptor family.
Q34704519SmgGDS regulates cell proliferation, migration, and NF-kappaB transcriptional activity in non-small cell lung carcinoma
Q36895457Smoking and lung cancer: future research directions
Q37502708Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC.
Q24648133Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer
Q37235024Somatic pharmacogenomics in cancer
Q93083893Sortilin as a new membrane inhibitor of EGFR trafficking for overcoming resistance to EGFR inhibitors in non-small cell lung cancer
Q64890079Stapled EGFR peptide reduces inflammatory breast cancer and inhibits additional HER-driven models of cancer.
Q38674296Stem Cell Therapy for Interstitial Cystitis/Bladder Pain Syndrome
Q41942436Stimulation of prolactin receptor induces STAT-5 phosphorylation and cellular invasion in glioblastoma multiforme
Q37840092Strategies for tumor-directed delivery of siRNA.
Q35968384Strategies to overcome resistance to targeted protein kinase inhibitors
Q38525856Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
Q35017477Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay
Q33810641Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer
Q39025002Structural bioinformatics-based identification of EGFR inhibitor gefitinib as a putative lead compound for BACE.
Q90179057Structural characterization of EGFR exon 19 deletion mutation using molecular dynamics simulation
Q37122918Structure and clinical relevance of the epidermal growth factor receptor in human cancer
Q27644014Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity
Q35673332Sulforaphane attenuates EGFR signaling in NSCLC cells
Q37699402Suppression of osteopontin inhibits chemically induced hepatic carcinogenesis by induction of apoptosis in mice
Q36311791Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis
Q37227994Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy
Q34635475Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib
Q39429719Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug-resistance in vitro and in vivo
Q38897130Synthesis, reactivity, and biological activity of gold(I) complexes modified with thiourea-functionalized tyrosine kinase inhibitors
Q33587012Synthetic lethal therapy for KRAS mutant non-small-cell lung carcinoma with nanoparticle-mediated CDK4 siRNA delivery
Q37214774Systematic discovery of complex insertions and deletions in human cancers.
Q38194591Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond
Q38264440Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond
Q92993100TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations
Q42582783Target therapy in NSCLC patients: Relevant clinical agents and tumour molecular characterisation
Q36920799Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectives
Q35953128Targeted cancer therapy
Q36786085Targeted cancer therapy: promise and reality
Q36054970Targeted therapies for lung cancer: clinical experience and novel agents
Q37956110Targeted therapies: how personal should we go?
Q49956245Targeted therapy of brain metastases: latest evidence and clinical implications.
Q37293656Targeting SHP2 for EGFR inhibitor resistant non-small cell lung carcinoma
Q37410635Targeting SOD1 reduces experimental non–small-cell lung cancer
Q36580144Targeting Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer by Inducing Epidermal Growth Factor Receptor Degradation via Methionine 790 Oxidation
Q90481579Targeting microtubules sensitizes drug resistant lung cancer cells to lysosomal pathway inhibitors
Q36804444Targeting signal transduction in pancreatic cancer treatment
Q91620717Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update
Q37741531Targeting the Mammalian Target of Rapamycin in Lung Cancer.
Q36742629Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations
Q34205052Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Q41825773Targeting the tumor-promoting microenvironment in MET-amplified NSCLC cells with a novel inhibitor of pro-HGF activation.
Q36077604Temporal resolution of autophosphorylation for normal and oncogenic forms of EGFR and differential effects of gefitinib.
Q27010154The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics
Q38166599The Biological Role of PI3K Pathway in Lung Cancer
Q49887941The E3 ubiquitin ligase NEDD4 mediates cell migration signaling of EGFR in lung cancer cells.
Q54498075The ERBB network: at last, cancer therapy meets systems biology.
Q37135372The ERBB3 receptor in cancer and cancer gene therapy
Q34558080The HER family and cancer: emerging molecular mechanisms and therapeutic targets
Q37716667The Hippo signaling pathway provides novel anti-cancer drug targets
Q35078950The Molecular Crosstalk between the MET Receptor Tyrosine Kinase and the DNA Damage Response-Biological and Clinical Aspects
Q58694197The Network of Non-coding RNAs in Cancer Drug Resistance
Q52880165The Role of Dysregulated MicroRNA Expression in Lung Cancer.
Q38199934The Role of STAT3 in Non-Small Cell Lung Cancer
Q24649549The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Q37709481The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations
Q28268061The concept of synthetic lethality in the context of anticancer therapy
Q37077933The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations
Q39353140The crossregulation between ERK and PI3K signaling pathways determines the tumoricidal efficacy of MEK inhibitor
Q26753387The dark matter of the cancer genome: aberrations in regulatory elements, untranslated regions, splice sites, non-coding RNA and synonymous mutations
Q47138128The efficacy of 40 mg versus dose de-escalation to less than 40 mg of afatinib (Giotrif) as the first-line therapy for patients with primary lung adenocarcinoma harboring favorable epidermal growth factor mutations.
Q35076292The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutations
Q40323538The epidermal growth factor receptor (EGFR)-S442F mutant displays increased affinity for neuregulin-2beta and agonist-independent coupling with downstream signalling events
Q36268324The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what's genetics got to do with it?
Q37839576The epithelial cell and lung cancer: the link between chronic obstructive pulmonary disease and lung cancer
Q40399733The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity
Q37098747The immunopharmacologic potential of Semaxanib and new generation directed therapeutic drugs: Receptor tyrosine kinase regulation with anti-tumorigenensis/angiogenesis properties
Q36303828The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy
Q91709281The impact of systemic precision medicine and immunotherapy treatments on brain metastases
Q40169126The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272.
Q92534345The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models
Q35133782The p110alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation
Q36219713The phosphoinositide 3-kinase signalling pathway as a therapeutic target in squamous cell carcinoma of the head and neck.
Q37724259The potential role of insulin-like growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer
Q35167981The proliferative effects of Pyropia yezoensis peptide on IEC-6 cells are mediated through the epidermal growth factor receptor signaling pathway
Q36704645The role of STATs in lung carcinogenesis: an emerging target for novel therapeutics
Q24616659The role of Src in solid tumors
Q42095201The role of cooperativity with Src in oncogenic transformation mediated by non-small cell lung cancer-associated EGF receptor mutants
Q33779663The role of metabolic tumor volume (MTV) measured by [18F] FDG PET/CT in predicting EGFR gene mutation status in non-small cell lung cancer
Q36274952The survival kinases Akt and Pim as potential pharmacological targets
Q96231168The top 100 cited articles in lung cancer - a bibliometric analysis
Q54940651The value of radial endobronchial ultrasound-guided bronchial brushing in peripheral non-squamous non-small cell lung cancer.
Q37755154Theme: oncology--molecular mechanisms determining the efficacy of EGF receptor-specific tyrosine kinase inhibitors help to identify biomarker candidates
Q34061302Therapeutic potential of targeting the oncogenic SHP2 phosphatase
Q37690755Therapeutic targeting of EGFR in malignant gliomas
Q92134589Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
Q39290667Threonine 2609 phosphorylation of the DNA-dependent protein kinase is a critical prerequisite for epidermal growth factor receptor-mediated radiation resistance
Q36050719Throwing new light on lung cancer pathogenesis: updates on three recent topics
Q36141341Tissue biomarkers for prostate cancer radiation therapy
Q64279348Trans-3,5,4´-trimethoxystilbene reduced gefitinib resistance in NSCLCs via suppressing MAPK/Akt/Bcl-2 pathway by upregulation of miR-345 and miR-498
Q50288598Trans-autophosphorylation of activated ligand-responsive EGFR mutant dimers
Q33306709Transcriptional profiling of non-small cell lung cancer cells with activating EGFR somatic mutations
Q37448428Transcriptomic analysis of pathways regulated by toll-like receptor 4 in a murine model of chronic pulmonary inflammation and carcinogenesis
Q39976030Tumor dependence on the EGFR signaling pathway expressed by the p-EGFR:p-AKT ratio predicts erlotinib sensitivity in human non-small cell lung cancer (NSCLC) cells expressing wild-type EGFR gene
Q46590868Tyrosine kinase activating mutations in human malignancies: implications for diagnostic pathology
Q37894095Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive
Q48128121Uncommon frame-shift exon 19 EGFR mutations are sensitive to EGFR tyrosine kinase inhibitors in non-small cell lung carcinoma.
Q37431491Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics
Q36173303Unlocking Pandora's box: personalising cancer cell death in non-small cell lung cancer
Q34474427Using iTRAQ combined with tandem affinity purification to enhance low-abundance proteins associated with somatically mutated EGFR core complexes in lung cancer.
Q35602598Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib
Q47893937Utility of urinary circulating tumor DNA for EGFR mutation detection in different stages of non-small cell lung cancer patients
Q54325987What new therapeutic targets exist for EGFR-mutant NSCLC?
Q37202390Yu Ping Feng San reverses cisplatin-induced multi-drug resistance in lung cancer cells via regulating drug transporters and p62/TRAF6 signalling.
Q33870872ZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brain
Q84170796[Histology-based algorithm in the molecular diagnosis of mutations of the Epidernal Growth Factor Receptor (EGFR) in non-small cell lung cancer]
Q54548364[Research progress in non-small cell lung cancer with concomitant EML4-ALK fusion gene and EGFR gene mutation].
Q54584669[Role of erlotinib 100 mg/d in the treatment of advanced adenocarcinoma lung cancer failed to previous chemotherapy].
Q91807615microRNAs Tune Oxidative Stress in Cancer Therapeutic Tolerance and Resistance
Q39373570p14(ARF) inhibits the growth of lung adenocarcinoma cells harbouring an EGFR L858R mutation by activating a STAT3-dependent pro-apoptotic signalling pathway
Q53355086ras Oncogene triggers up-regulation of cIAP2 and XIAP in intestinal epithelial cells: epidermal growth factor receptor-dependent and -independent mechanisms of ras-induced transformation.
Q46707269siRNA targeting against EGFR, a promising candidate for a novel therapeutic application to lung adenocarcinoma
Q41592800siRNA-mediated inactivation of HER3 improves the antitumour activity and sensitivity of gefitinib in gastric cancer cells

Search more.